Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept plus FOLFOX in KRAS mutant mCRC liver metastases
NCT01646554Phase 3Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2012
- Primary completion
- Dec 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
A Phase 3 trial of aflibercept in colorectal cancer (CRC), sponsored by European Organisation for Research and Treatment of Cancer. Planned start Dec 2012; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01646554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01646554.